Today, we approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death.
Today, we approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. t.co/pul33IEnIw
The mRNA COVID-19 vaccines have… pic.twitter.com/HkZlPX8jwW
— U.S. FDA (@US_FDA) August 22, 2024
13 percent of Americans have worn a facemask in the last week. New Vaccines are coming.
www.axios.com/2024/08/22/poll-covid-health-risk-axios-ipsos